I guess I misunderstood you hank. I actually do think the announcement will mention the statistical significance one way or the other, as that is what “topline” basically means. I thought you were saying that if the trial doesn’t reach statistical significance, that would be the “kiss of death” like others who have stated that the price would go to zero and bankrupt the company. I don’t believe this is true, and those who believe that probably haven’t been paying attention. It appears to me that Linda Powers is preparing for all of the potential outcomes. After they receive the statistical analysis and review it with their SAB, it’s possible that Northwest Bio will meet with the FDA (virtually) to discuss the data and potential pathways to approval, prior to the public announcement, to ensure that the announcement will be well received.
News 
Market Data 
Discover 
